V8/H8 Diagnostic Ultrasound System, V7/H7 Diagnostic Ultrasound System, V6/H6 Diagnostic Ultrasound System

The Samsung Medison V8/H7/H6 series are advanced diagnostic ultrasound systems designed to provide comprehensive imaging capabilities across numerous clinical specialties through various operational modes, including 2D, Doppler, ElastoScan, and 3D/4D imaging. These systems incorporate AI-driven NerveTrack technology for enhanced pre-injection peripheral nerve visualization and segmentation, aiming to support clinicians in diagnostic procedures and fluid analysis.

The Samsung Medison V8/H8, V7/H7, and V6/H6 Diagnostic Ultrasound Systems are general-purpose, mobile, software-controlled devices designed to acquire ultrasound images and analyze body fluids for clinical diagnosis. These systems support a wide range of clinical applications, including fetal/obstetrics, abdominal, gynecological, intra-operative, pediatric, small organ, cephalic (neonatal and adult), trans-rectal, trans-vaginal, musculoskeletal, urological, cardiac (adult and pediatric), thoracic, trans-esophageal (cardiac), and peripheral vessel imaging. They operate in various modes such as 2D, Color Doppler, Power Doppler, M mode, Pulsed Wave (PW) Doppler, Continuous Wave (CW) Doppler, Tissue Doppler Imaging (TDI), Tissue Doppler Wave (TDW), ElastoScan, combined modes, multi-image (dual, quad), and 3D/4D modes. The systems also feature new transducers (L3-22, LA2-16S, CA1-7AD for V6/H6, LM2-18 for V8/H8) and new biopsy guides, along with the ability to measure anatomical structures and offer analysis packages. A key technological advancement in these systems is the AI-based NerveTrack segmentation function, designed for pre-injection use only and not as a guide for needling. NerveTrack provides contour segmentation for nerves like the interscalene brachial plexus (ISBP) and axillary brachial plexus (AxBP), as well as surrounding structures such as bone, blood vessels, and muscle, displayed with distinct colors. Validation of the NerveTrack AI algorithm demonstrated an average detection accuracy of 90.3% and a speed of 3.61 FPS on a dataset of 2,146 images from 18 Korean subjects. For segmentation, the accuracy was 98.69% and speed was 3.62 FPS, tested on 3,836 images from 11 Korean subjects. The system's performance was evaluated across different BMI subgroups, showing good generalizability, with the maximum depth of detected nerves being 3.31 cm. The systems display real-time mechanical and thermal indices and are intended for use by appropriately trained healthcare professionals.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the NerveTrack AI algorithm's performance (accuracy and speed) vary across different nerve types beyond ISBP and AxBP, and in diverse patient populations with varying ethnicities and anatomical characteristics not represented in the Korean-only test dataset?; What are the specific imaging characteristics or limitations of the new transducers (L3-22, LA2-16S, CA1-7AD, LM2-18) compared to previously available transducers for these systems, particularly in challenging imaging scenarios?; Given that NerveTrack is for pre-injection use only, what are the quantifiable benefits it provides to clinicians in terms of pre-procedural planning or accuracy improvement for peripheral nerve blocks compared to standard ultrasound guidance without this feature?; The NerveTrack testing data mentions a maximum detected nerve depth of 3.31 cm; how does the system's performance degrade for nerves located at greater depths, and what is the effective depth limit for reliable segmentation?; Considering the NerveTrack performance was validated on data acquired with Samsung ultrasound devices including the V8, how might variations in image acquisition parameters or operator skill influence the AI's real-world effectiveness?